Results 31 to 40 of about 3,785 (146)

Chronic Human Herpes Virus 8 Infection Successfully Treated With Valganciclovir

World Allergy Organization Journal, 2009
Background: A 57 year old Italian female with a 3 year history of constituitional symptoms with non-HIV Kaposi sarcoma was referred to the immunology clinic.
James J. Yun, MBBS, Veronica Preda, MBBS(Hons), BSc(Med), Brad Frankum, BMed(Hons), FRACP   +2 more
doaj   +1 more source

Hearing loss in children with congenital cytomegalovirus infection

Revista Portuguesa Otorrinolaringologia e Cirurgia de Cabeça e Pescoço, 2023
Objective: To study the prevalence of hearing loss in children with congenital Cytomegalovirus infection and the influence of the type of maternal infection, symptoms and neonatal treatment with valganciclovir.
Gonçalo Caetano Oliveira, Filipa Morgado, Mariana Santos, Clara Mota, Ricardo Matos, Raquel Robles, Rui Fonseca   +6 more
doaj   +1 more source

Establishment and Evaluation of a Parametric Population Pharmacokinetic Model Repository for Ganciclovir and Valganciclovir

Pharmaceutics, 2023
Background: Ganciclovir and valganciclovir are used for prophylaxis and treatment of cytomegalovirus infection. However, there is great interindividual variability in ganciclovir’s pharmacokinetics (PK), highlighting the importance of individualized ...
Wenyu Yang, W. Mak, A. Gwee, Meng Gu, Yue Wu, Yu-He Shi, Qingfeng He, X. Xiang, Bing Han, Xiao Zhu   +9 more
semanticscholar   +1 more source

Congenital cytomegalovirus infection: features of the clinical course and catamnesis according to own observations

Журнал инфектологии, 2022
Congenital cytomegalovirus infection is the most common congenital infection, occurs in 0.6-5% of newborns worldwide, and is considered the leading non-genetic cause of sensorineural hearing loss in children.
E. V. Antsiferova, T. E. Taranushenko, D. G. Geninova, L. N. Karpova, L. A. Filippova, K. I. Karaganova, L. S. Karpova   +6 more
doaj   +1 more source

Optimising graft survival in endothelial keratoplasty for endothelial failure secondary to cytomegalovirus endotheliitis

Journal of Ophthalmic Inflammation and Infection, 2019
Background There is limited information regarding Descemet stripping automated endothelial keratoplasty (DSAEK) for endothelial failure secondary to cytomegalovirus (CMV) endotheliitis. Treatment is difficult with high recurrence rates.
Milton C. Chew, Donald T. Tan, Soon-Phaik Chee, Lim Li   +3 more
doaj   +1 more source

Valganciclovir is not associated with decreased EBV infection rate in pediatric kidney transplantation

Frontiers in Pediatrics, 2023
IntroductionPrimary infection or reactivation of Epstein-Barr Virus (EBV) is a significant cause of morbidity and mortality in pediatric kidney transplantation.
Elodie Cheyssac, Hamidou Savadogo, Nathan Lagoutte, Véronique Baudouin, Marina Charbit, Robert Novo, Anne-Laure Sellier-Leclerc, Marc Fila, Stéphane Decramer, Elodie Merieau, Ariane Zaloszyc, Jérôme Harambat, Gwenaelle Roussey   +12 more
doaj   +1 more source

Optimizing ganciclovir and valganciclovir dosing regimens in pediatric patients with cytomegalovirus infection: a spotlight on therapeutic drug monitoring

Expert Review of Clinical Pharmacology, 2023
Introduction Infants and immunocompromised children with cytomegalovirus (CMV) infection have significant morbidity and mortality. Ganciclovir (GCV) and its oral prodrug valganciclovir (VGCV) are the major antiviral options of choice for the prophylaxis ...
Qiu-Yue Li, J. N. van den Anker, Yue-E. Wu, Guo-Xiang Hao, Wei Zhao   +4 more
semanticscholar   +1 more source

Efficacy and Safety of Antiviral Agents in Preventing Allograft Rejection Following CMV Prophylaxis in High-Risk Kidney Transplantation: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Frontiers in Cellular and Infection Microbiology, 2022
Many antiviral agents have been studied in clinical trials for allograft rejection prevention following cytomegalovirus (CMV) prophylaxis in high-risk kidney transplant patients. However, data on the most effective and safest treatment are lacking.
Narisa Ruenroengbun, Tunlanut Sapankaew, Kamolpat Chaiyakittisopon, Pakpoom Phoompoung, Thundon Ngamprasertchai   +4 more
doaj   +1 more source

Population Pharmacokinetic and Pharmacodynamic Analysis of Valganciclovir for Optimizing Preemptive Therapy of Cytomegalovirus Infections in Kidney Transplant Recipients

Antimicrobial Agents and Chemotherapy, 2023
This study aimed to develop a population pharmacokinetic/pharmacodynamic (PK/PD) model of valganciclovir for preemptive therapy of cytomegalovirus (CMV) infection in kidney transplant patients.
P. Cojutti, A. Heffernan, T. Tängdén, P. Della Siega, C. Tascini, J. Roberts, F. Pea   +6 more
semanticscholar   +1 more source

Valganciclovir for cytomegalovirus preemptive therapy in patients following allogeneic hematopoietic stem cell transplantation

Di-san junyi daxue xuebao, 2020
Objective and;To evaluate the clinical value of valganciclovir in preemptive treatment of cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT) by comparing the efficacy of the drug with other conventional ...
LU Xuan, YAN Han, XIA Linghui
doaj   +1 more source